In Brief
The importance of IFNls in the respiratory tract remains puzzling. Galani and colleagues show that IFNls provide front-line antiviral protection without activating inflammation. When infection escapes IFNl control, type I IFNs come into play to enhance antiviral defenses and trigger pro-inflammatory responses essential for confronting infection but causing immunopathology.
INTRODUCTION
Influenza constitutes a major public health concern despite available antiviral drugs and vaccines against seasonal strains (Medina and García-Sastre, 2011) . Influenza A virus (IAV) causes widespread infection in humans which can become life threatening, leading to pneumonia and acute respiratory distress syndrome (ARDS). Protection from IAV infection requires the induction of effective antiviral immunity that mediates optimal viral clearance without compromising host fitness. This process needs to be finely tuned, as insufficient antiviral immunity results in higher viral load and direct viral damage to the respiratory epithelium while excessive antiviral immunity causes hostdamaging inflammation. Therefore, IAV-induced lung injury, triggering pneumonia and ARDS, can be the consequence of two conceptually independent but interrelated processes, the ''yinyang'' of which remains poorly understood.
A strong barrier to respiratory viral infections including IAV is provided by the mucosal innate immune system (Iwasaki and Pillai, 2014 ). Under the current paradigm, infection of the respiratory epithelial layer triggers the production of type I IFNs which signal via the IFNaR1 and IFNaR2 heterodimeric complex to upregulate hundreds of genes collectively known as interferonstimulated genes (ISGs) that inhibit viral replication, degrade viral nucleic acids, and induce viral resistance to neighboring cells (McNab et al., 2015) . This is followed by the production of inflammatory cytokines and chemokines and by the recruitment of neutrophils, monocytes, and NK cells which take up and inactivate the virus, kill virally infected cells, and guide subsequent innate and adaptive immune responses that mediate ultimate viral clearance (Iwasaki and Pillai, 2014) . However, this inflammatory process can also lead to collateral damage and immunopathology. Transcriptomics analyses of lethal versus sublethal IAV infection have strongly linked early innate immunity signatures comprising inflammatory cytokines (TNF, IL-1b, IL-6), chemokines (CCL2, CCL3, CCL4, CXCL1), and neutrophil chemotaxis genes with acute death of the infected animals (Brandes et al., 2013) . In addition, innate cytokines such as TNF and IL-1b, and various chemokines, have been shown to directly account for host damage caused by IAV infection (Iwasaki and Pillai, 2014) . Still, the key determinants of protective versus detrimental effects of antiviral defense remain poorly characterized, while specific mechanistic details are lacking.
Lambda IFNs (IFNls, type III IFNs or IL-28 and IL-29) constitute a newer class of interferons that share homology, expression patterns, and antiviral functions with type I IFNs (Lazear et al., 2015b; Wack et al., 2015) . They consist of four members in humans (IFNl1 or IL-29, IFNl2 or IL-28A, IFNl3 or IL-28B, and IFNl4) and two in mice (IFNl2 or IL-28A, IFNl3 or IL-28B) (Kotenko et al., 2003; Prokunina-Olsson et al., 2013; Sheppard et al., 2003) and are abundantly expressed at mucosal interfaces such as the respiratory and gastrointestinal tracts following microbial infection Lazear et al., 2015b) . Although IFNls signal through a unique heterodimeric receptor complex consisting of IFNlR1 (IL28Ra) and IL-10Rb, they induce downstream signaling that appears remarkably similar to that of type I IFNs, driving the expression of ISGs and the induction of antiviral responses (Durbin et al., 2013; Mendoza et al., 2017) . It has therefore been difficult to identify unique gene expression patterns for IFNls even in global transcriptomics analyses (Bolen et al., 2014; Kohli et al., 2012) . This has prompted speculation that IFNls are functionally redundant to type I IFNs and that their importance is governed by ligand availability and receptor distribution (Durbin et al., 2013) . Indeed, in the gastrointestinal tract the two IFN systems are compartmentalized; IFNls act on intestinal epithelial cells and clear infections there, while type I IFNs act on non-epithelial cells including lamina propria cells in line with the differential expression of their receptors (Herná ndez et al., 2015; Mahlakõ iv et al., 2015; Pott et al., 2011) . In the respiratory tract, however, such clear-cut distinction between receptor-ligand availability in epithelial and immune cells has not been described. IFNls are abundantly produced by respiratory epithelial cells, but dendritic cells (DCs) and macrophages are also good sources (Ank et al., 2008; Contoli et al., 2006) . Similarly, respiratory epithelial cells express high amounts of the IFNl receptor, but lung DCs can also respond to IFNls (Koltsida et al., 2011) . It has therefore been difficult to assign distinct nonredundant roles to IFNls. Although Ifnlr1
Ifnar1
À/À mice are more susceptible to lethal IAV infection than Ifnar1 À/À mice, studies in Ifnlr1 À/À mice have failed to demonstrate a ''ratelimiting'' role of IFNls per se in suppressing viral load or mediating antiviral protection (Ank et al., 2008; Crotta et al., 2013; Mordstein et al., 2008; Mordstein et al., 2010) . This has also been the case for other respiratory viral infections beyond IAV (Mordstein et al., 2010) , leaving unanswered the questions of whether and how IFNls are involved in antiviral defense in the lung. Here, we have used a systematic approach involving global Ifnlr1
À/À , and Ifnlr1 À/À Ifnar1 À/À animals; neutrophil or epithelial cell-specific Ifnlr1 À/À animals; and novel Ifnl2 Egfp reporter mice to uncover unique non-redundant functions of IFNls in IAV infection. Our findings demonstrate that IFNls are the first and predominant IFNs produced that mediate front-line antiviral protection without activating inflammation. They also reveal a clever dichotomy of the antiviral response based on the type I and III IFN systems that aims to optimally clear viral infections without activating inflammation unnecessarily and compromising host fitness.
RESULTS

IFNls Are the Earliest and Predominant IFNs Produced during Influenza Virus Infection
In order to uncover any unique non-redundant functions of IFNls, we pursued a systematic approach involving a wide range of doses of IAV infection in mice; multiple endpoints (including early endpoints to study initial events); and multiple parameters for monitoring viral spread, antiviral and inflammatory responses, and tissue damage ( Figure 1A ). We established 10 pfu of IAV as the sublethal dose corresponding to 0.1 LD50, and 100 pfu as the lethal dose consistently killing $50% of wild-type (WT) animals (LD50). Higher doses caused very severe disease and acute lethality ( Figure 1B) . At 10 pfu, weight loss was limited to only 10% of the total weight, while at 100 pfu this reached 30% ( Figure 1C ).
Viral RNA load and HA protein amounts in the lung were proportional to the initial IAV dose administered ( Figures S1A and  1D ). Inflammatory and tissue destruction parameters also followed these trends. At 10 pfu, inflammatory cell infiltration in the bronchoalveolar lavage (BAL) was evident at day 3 postinfection (p.i.) and increased thereafter ( Figure 1E ). At 100 pfu and higher doses, this occurred more rapidly and was aggravated ( Figure 1E ). Initial inflammatory cell infiltrates mostly comprised neutrophils with the remaining being monocytes and macrophages or lymphocytes (Figures S1B-S1D). Consistently, neutrophil infiltration markedly increased in lung tissue sections ( Figure S1E ). Lung compliance, a measure of lung's ability to stretch and expand, was reduced by 65% at day 10 p.i. with 100 pfu, while total lung resistance, the opposition to airflow during inspiration and expiration, was increased by over 100% (Figures 1F and S1F ). In contrast, the impact of the 10 pfu dose to these parameters was milder (Figures 1F and S1F) . This was in agreement with the histopathological analysis of the lung revealing increased and earlier presence of leukocytic infiltrates and parenchymal destruction following administration of 100 compared to 10 pfu of IAV ( Figure S1G ).
The IAV dose used differentially affected the expression of IFNs. Although IFNls were rapidly induced at both low and high viral doses, type I IFNs required higher viral loads. Thus, at 10 pfu IFNls were already detectable in the BAL at days 1 and 2 p.i. (Figure 1G ) and were upregulated thereafter, while type I IFNs were produced only from day 3 p.i. onward (Figures 1H and 1I) , in agreement with the rise in viral load. Similarly, at 100 pfu IFNls were already expressed at day 1 p.i., while type I IFNs were not measurable in the BAL before day 2. With increasing viral doses, though, the production of type I IFNs was gradually shifted to earlier time points. Among type I IFNs, the most abundant species was IFNa ( Figure 1H ), although IFNb was also measurable ( Figure 1I ). These observations raised the possibility that the very initial viral spread, occurring during the first days of infection, could be solely controlled by IFNls. F   10  100  500  5000  50000  500000  10  100  500  5000  50000  500000  10  100  500  5000  50000  500000  10  100  500  5000  50000  500000  10  100  500  5000  50000 (G-I) IFNl, IFNa, and IFNb concentrations measured in the BAL of IAV-infected mice. For the highest infection doses, measurements until day 3 or 5 p.i. are shown due to lethality. Dotted lines indicate the limit of detection. Data are expressed as mean ± SEM of n = 12-20 for 10 and 100 pfu, and n = 3-5 mice for the rest of viral doses pooled from two to three independent experiments. For survival, weight loss and dynamic compliance data are from n = 5-10 mice per group pooled from two independent experiments. p.i., post-infection. Please also see Figure S1 . WT or Ifnar1 À/À animals ( Figure 2D ). Infiltrates comprised mostly neutrophils, although monocytes and macrophages or lymphocytes were also present ( Figure 2E ). Notably, this was associated with heightened production of IFNa, but not IFNb, in Ifnlr1 À/À animals and higher expression of cytokines and chemokines such as TNF, IL-6, IFNg, CCL2, CCL3, CCL4, CXCL1, CXCL9, and CXCL10 ( Figures 2F and S2C ) implicated in feedforward inflammatory circuits during early IAV infection linked to acute lung injury (Brandes et al., 2013) . On the contrary, the production of most of these mediators in Ifnar1 À/À animals was largely sup- 
IFNls
, mice. There was increased presence of inflammatory cell infiltrates in peribronchial and parenchymal areas of the lung at day 7 p.i. (Figure 2G ) and deteriorated lung function indicated by reduced dynamic compliance ( Figure 2H ) and increased total lung resistance ( Figure 2I) 3B ). This pattern was translated into higher infectious virus load at day 3 p.i. in Ifnlr1
, and Ifnlr1
mice, indicating the importance of both IFN systems in early antiviral protection in this setting ( Figure 3C ). In the BAL, Ifnlr1
and Ifnlr1
Ifnar1
À/À mice exhibited higher inflammatory cell numbers at days 3 and 4 p.i., ( Figure 3D ), while Ifnar1 À/À mice did not differ from WT animals at these early time points ( Figure 3D ). Infiltrates comprised mostly neutrophils, but monocytes, macrophages, and lymphocytes were present as well ( Figure 3E ). Ifnlr1 À/À mice had also higher IFNa, CCL3, and CCL4 amounts compared to WT animals, while the expression of IFNl, IFNb, and most other pro-inflammatory cytokines and chemokines measured did not differ ( Figures 3F and S2D ). By comparison, the production of these mediators in Ifnar1 À/À mice was markedly suppressed at day 3 p.i. as significantly lower concentrations of IFNa, TNF, IL-1b, IL-6, CCL2, CCL3, CCL4, CXCL1, CXCL5, CXCL9, and CXCL10 were observed in the BAL of infected animals. Suppression, however, was transient, since TNF, IL-1b, and CXCL9 were rapidly upregulated from day 4 p.i. onward to amounts even higher than those of WT ( Figures 3F  and S2D ), while most other mediators reached or surpassed WT amounts by day 8 ( Figure S2E ). IFNl production, on the other hand, was not affected in Ifnar1 À/À mice before day 3 p.i. (Figure S2D ). In agreement with these patterns, inflammatory cell infiltrates in peribronchial and parenchymal areas of the lung were markedly increased in Ifnlr1 À/À and Ifnlr1
compared to WT and Ifnar1 À/À mice ( Figure 3G ). Moreover, dynamic compliance was significantly reduced ( Figure 3H ) and total lung resistance increased ( Figure 3I ) in Ifnlr1 À/À and
Immunopathology affected viability independently of weight loss ( Figure S2F ). Ifnlr1 À/À mice exhibited higher lethality earlier on, with $30% of the animals dying by day 8 compared to WT mice which were all alive, and $65% dying overall ( Figure 3J ). This phenotype was even more severe in Ifnar1 À/À and
Ifnlr1
À/À
Ifnar1
À/À mice, reaching 30% and 40% by day 8, respectively, and over 80% lethality in the long term. Lethality of Ifnar1 À/À mice could also be attributed to immunopathology, as the initial reduction in cytokine and chemokine gene expression led to an aberrant pro-inflammatory response later on (Figures 3F, S2D and S2E, and S2G and S2H) . Thus, both type I and type III IFNs are essential for confronting lethal IAV infection, through disparate mechanisms, and cannot be substituted from each other in this process. Type I IFNs also constitute major inducers of the initial wave of pro-inflammatory cytokine and chemokine production that causes immunopathology.
IFNls Are Produced from Epithelial Cells and Pro-inflammatory Cytokines from Neutrophils during Early Viral Infection
To monitor IFNl expression in vivo and clarify the mechanism of action of type III IFNs in viral infection, we generated Ifnl2
Ifnar1
À/À mice were exposed to sublethal (10 pfu) IAV infection. (H and I) Baseline-corrected dynamic compliance (H) and total lung resistance (I) determined at day 7 p.i. Data are expressed as mean ± SEM of n = 5-10 mice for days 1, 2, and 5 p.i. and n = 8-20 for days 3 and 4 p.i. pooled from two to four independent experiments. For dynamic compliance and total lung resistance, data are from n = 9-12 mice per group pooled from two independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate significant differences compared to WT mice. p.i., post-infection. Please also see Figure S2 . reporter mice in which we genetically targeted to the 3 0 end of the Ifnl2 gene the egfp coding sequence, preceded by the selfcleavable peptide 2A ( Figure 4A) . Results from this model should predict both IFNl2 and IFNl3 expression patterns, as the promoter areas of these two genes are remarkably similar and coregulated (Durbin et al., 2013) . The presence of the targeted allele was confirmed by PCR-based genotyping (Figures S3A and S3B) , and the functionality of the model was validated in TLR-stimulated bone marrow-derived DC subsets (Figures S3C and S3D) . Using these mice, we determined the spatiotemporal expression of IFNl following lethal IAV infection. EGFP was induced at day 2 p.i. and was greatly upregulated at day 3 (Figure 4B ). At day 2, EGFP presence was mostly localized to EPCAM + epithelial cells in the large conducting airways, although some SpC + type II pneumonocytes were also found to express the transgene ( Figure 4C ). At day 3, EGFP could also be seen further down across the bronchial tree in intermediate size airways (data not shown) and sparse CD45 + leukocytes in the lung parenchyma. These kinetics correlated with viral RNA and Egfp mRNA expression in whole lung (Figures S3E and S3F) . To corroborate these data, we sorted to high purity lung epithelial cell and leukocyte populations including neutrophils, alveolar macrophages, inflammatory monocytes, T cells, B cells, and DCs, from both sham and IAV-treated mice (Figures 4D and S3G Figure 4E ), which seem to compose the scarce leukocytes expressing EGFP in the lung parenchyma. This was consistent with high viral load in these cells, the main trigger of IFN expression ( Figure 4F ). As CD45 + cells represent a fraction of total lung cells, and as CD45
less than 4% of total leukocytes in the lung ( Figure S3H ), these data confirm that the major source of IFNl production during early IAV infection is the respiratory epithelium. We also observed that neutrophils were the main cells producing pro-inflammatory mediators in response to IAV infection. Thus, at day 3 p.i., Tnf, Il1b, and Cxcl1 mRNA were mostly restricted to neutrophils with little presence in other cells, while Il6 and Ccl2 were also produced by other cell populations (Figures 4G and S3I) . As neutrophils are the most abundant infiltrating cells early on, constituting >75% of inflammatory cells in the BAL and >25% of total leukocytes in the lung by day 3 p.i. (Figure S3H ), these data highlight their importance in driving the first wave of pro-inflammatory mediator production. Neutrophils also expressed high amounts of Ifnlr1 and Il10rb mRNA, as did EPCAM + epithelial cells (Figures 4H and S3I) . In contrast, alveolar macrophages, inflammatory monocytes, and T and B lymphocytes did not express Ifnlr1, while DCs exhibited lower expression. By comparison, Ifnar1 mRNA was ubiquitously found in all cell populations examined, with the exception of alveolar macrophages ( Figure S3I ). Ifna and Ifnb expression was also broader ( Figure S3I ). Notably, at the tissue level IFNlR1-bearing neutrophils were found in close proximity to EGFP-expressing cells ( Figure 4I ), raising the possibility that IFNls signal in both neutrophils and epithelial cells to control early viral infection.
IFNls Act on Both Respiratory Epithelial Cells and Neutrophils to Optimally Confront Initial Viral Replication and Spread
We next sought to determine the relative contribution of IFNl signaling in epithelial cells and neutrophils in confronting initial viral spread. Using immunofluorescence microscopy for nucleoprotein (NP), a protein critical for IAV replication, we observed that the bulk of virus load at day 3 p.i. with 100 pfu was localized to the airway epithelium, although alveolar epithelial cells were occasionally infected too ( Figure 5A ). However, we also observed that a small number of NP + cells were CD45 + , and some of them expressed Ly6G, pointing to the presence of virus in neutrophils as well (Figures 5A and 5B) .
To get quantitative data on viral spread in lung epithelial cells, and determine the effect of IFNls and type I IFNs in this process, we employed flow cytometry. NP presence was markedly increased in total EPCAM + epithelial cells from lung digests of S4A , and S4B).
To establish that IFNls act directly in the respiratory epithelium to mediate their antiviral effects, and to assess the involvement of neutrophil-specific IFNl signaling in this process, we crossed conditional Ifnlr1 fl/fl mice (Lin et al., 2016) with Sftpc Cre and S100a8 Cre mice ( Figures 5D and S4C) . Sftpc is expressed in the lung endoderm during development (but only type II pneumonocytes in the adult lung) and therefore broadly deletes Ifnlr1 Data are expressed as mean ± SEM of n = 5-10 mice for days 1 and 2 p.i. and n = 10-22 for days 3-5 p.i. pooled from two to four independent experiments. For dynamic compliance and total lung resistance, data are from n = 12-18 mice per group pooled from two independent experiments. For survival, data are from n = 36 mice for WT, n = 38 for Ifnlr1
, and n = 12 for Ifnlr1
Ifnar1
À/À mice pooled from two to four independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate significant differences compared to WT mice. p.i., post-infection. Please also see Figure S2 . in respiratory epithelial cells including airway and alveolar epithelial cells without affecting immune cells ( Figure S4D ) (Okubo and Hogan, 2004) . S100a8, on the other hand, is almost explicitly expressed in neutrophils and deletes Ifnlr1 in neutrophils but in no other immune or non-immune cell populations (Abram et al., 2014; Passegué et al., 2004 
À/À mice was not affected compared to WT animals ( Figure S4I ), suggesting that the increased pro-inflammatory response is most likely coming from leukocytes. Mice with specific deletion of Ifnlr1 in neutrophils (S100a8 Cre Ifnlr1 fl/fl mice) were also more susceptible to sublethal IAV infection. They had higher viral load than WT mice but did not differ significantly from them in inflammatory cell numbers or pro-inflammatory cytokines in the BAL (Figures 5E-5H, S4G, and S4H). IFNls therefore act directly at the respiratory epithelium to limit viral replication and spread and to prevent induction of pro-inflammatory responses in the lung. They also act on neutrophils to induce optimal antiviral defenses.
IFNls and Type I IFNs Differentially Control Neutrophil Antiviral and Pro-inflammatory Gene Expression Programs with Major Functional Consequences
To understand how type III IFNs modulate neutrophils to enhance antiviral defense, we generated comprehensive RNA-seq gene expression data from highly purified bonemarrow-derived neutrophils stimulated with IFNl or IFNa for 2, 4, 8, 16, and 24 hr, or treated with sham control (15 conditions in biological triplicates, i.e., 45 datasets in total) (Figures 6A and S5A) . Principle component analysis showed that samples clustered by treatment, indicating this as the main source of variation ( Figure 6B ). Following DESeq2 analysis with an adjusted p value cutoff of 0.01 (FDR 1%), 6,072 genes were differentially expressed in at least one of all possible pairwise comparisons across the 15 experimental conditions (Table S1 ). Using K-means clustering analysis, these were split into ten clusters that share expression patterns and may therefore be enriched for genes with similar functions ( Figure S5B and Table S2 ). Cluster 1, which contained the most highly upregulated genes of both groups, consisted almost exclusively of ISGs and some pattern recognition receptors (PRRs). Clusters 2-5, which contained genes with high or intermediate upregulation in the IFNa group but low or minimal induction in the IFNl group, comprised genes involved in inflammation and chemotaxis, as well as some ISGs and PRRs. Finally, clusters 6-10 concentrated mainly homeostatic and metabolic genes either minimally regulated in the two groups or downregulated.
Heatmaps generated on this basis for panels of key antiviral, pattern recognition, and inflammatory genes were revealing. IFNls and type I IFNs strongly induced numerous ISGs conferring antiviral resistance to cells including Isg15, Oas1, and Ifit genes ( Figure 6C and Table S3 ). Although the kinetics slightly differed, with IFNls triggering more prolonged and type I IFNs more transient gene expression, in both cases ISGs remained high for at least 24 hr, the latest time point used in this analysis. This was confirmed by qPCR analysis (Figures S5C and S5D ) and had profound consequences in the antiviral state of neutrophils. Thus, during infection with 100 pfu of IAV Ifnlr1
Ifnar1
À/À and Ifnlr1 
À/À mice exhibited high numbers of NP + neutrophils at day 4 p.i. (Figures 6D and S6B) . Notably, higher NP expression was associated with higher infectious virus presence in neutrophils, as sorted cells from the BAL of Ifnlr1
and Ifnlr1 À/À Ifnar1 À/À mice demonstrated an increased ability to infect epithelial cells in culture compared to WT controls (Figure 6E ). IFNls and type I IFNs also triggered the transcription of genes involved in pattern recognition, such as Ddx58, Ifih1, Tlr3, and Tlr7, but IFNa did so more potently ( Figure S6C ). However, although type I IFNs strongly induced the expression of numerous pro-inflammatory cytokines and chemokines including Tnf, Il1b, Il6, and Ccl2, IFNls lacked this response (Figures 6F and S6D ; Table S3 ). Moreover, treatment of highly At all cases, data are representative of one from three independent experiments. EPCAM, epithelial cell adhesion molecule; SpC, surfactant protein C. Please also see Figure S3 . purified neutrophils with IFNa in culture induced the production of TNF and IL-6 protein, whereas IFNl had no effect ( Figures  S6E and S6F ). Consistently, in sorted neutrophils from 10 pfu IAV-infected mice at day 4 p.i., pro-inflammatory gene expression was generally increased in Ifnlr1 À/À animals, while this was reduced in Ifnar1 À/À mice compared to WT controls (Figure 6G) . These studies suggest a selective role of type III IFNs in the induction of prolonged antiviral defenses in neutrophils, without the activation of inflammation. They also point to a major involvement of type I IFNs in the neutrophil-driven pro-inflammatory cascade in the lung that is induced following IAV infection.
Therapeutic Administration of Pegylated IFNl Limits Viral Spread, Inflammation, and Symptoms of Influenza Virus Infection
The potent antiviral and immune modulatory activities of IFNls prompted us to investigate their potential therapeutic activity in vivo by administering i.n. pegylated recombinant IFNl (PEGIFNl) to infected mice. We first noted that the i.n. administration of vehicle per se, post-infection, worsened the disease phenotype, a phenomenon that has been previously described (Smee et al., 2012 ). Although at a single i.n. the effect on survival was milder and non-significant ( Figure S7A ), repeated i.n. administration turned the otherwise LD50 dose of 100 pfu equivalent in terms of lethality to 50 LD50 or 5,000 pfu ( Figure S7B ). Still, treatment effectively ameliorated disease. In mice infected with 10 pfu of IAV ( Figure 7A ), a single i.n. administration of PEG-IFNl at day 2 p.i. led to high concentrations of IFNl in the lung ( Figure S7C ) and suppressed viral replication and spread, decreasing viral RNA and HA protein amounts by $50%, and infectious virus by $70% by day 5 ( Figures 7B, 7C , and S7D). It also reduced weight loss by 50% by day 5 and 30% by day 7 ( Figure S7E ) and halved inflammatory cell numbers in BAL including neutrophils ( Figures 7D and S7F) . Notably, PEG-IFNl treatment also prevented the induction of IFNa and IFNb (Figure S7G ) and inhibited the expression of several pro-inflammatory mediators including TNF, IFNg, CCL3, CCL4, CXCL9, and CXCL10 ( Figure S7H ). Consistently, peribronchial and parenchymal cell infiltration in histological lung sections was also decreased ( Figure 7E ), while lung function was improved. More specifically, PEG-IFNl administration reduced IAV-induced drop in dynamic compliance by 32% ( Figure 7F ) and increase in total lung resistance by 50% ( Figure S7I ). PEG-IFNl treatment was also effective in combating lethal IAV infection induced following challenge with 100 pfu of virus. When administered once at day 1 p.i., a time point analogous to day 2 p.i. of sublethal infection in terms of IAV load, PEG-IFNl markedly reduced viral spread in the lung ( Figures S7J and S7K ), decreased inflammatory cell infiltration in the BAL and weight loss ( Figures S7L and S7M) , and prolonged survival for several days while reducing overall death by one-third ( Figures 7G and  7H) . Moreover, when administered consecutively at days 1, 2, and 3 p.i., PEG-IFNl prevented acute lethality observed in this severe protocol of repeated i.n. manipulation ( Figures 7G and  7I ). This was most pronounced when PEG-IFNl was first administered at 6 hr p.i. compared to 24 hr, highlighting the importance of early PEG-IFNl administration for efficacy. Thus, IFNl treatment exerts potent therapeutic effects against IAV infection by inhibiting viral spread, reducing inflammation, and enhancing overall survival of infected animals.
DISCUSSION
Our study reveals that IFNls constitute the front line of antiviral defense in the respiratory tract, preceding that of type I IFNs and providing early infection control. In either sublethal or lethal IAV infection, IFNl expression is induced first, in excess amounts to these of type I IFNs, and acts locally at the epithelial barrier to limit initial viral spread without activating inflammation. This is in sharp contrast to type I IFNs, which come into play later on, once infection escapes IFNl control, to provide further antiviral resistance but at the same time induce pro-inflammatory responses essential for dealing with infection but also mediating tissue damage. Our study thus unravels unique non-redundant roles of IFNls in antiviral defense against respiratory viral infections and uncovers a sophisticated molecular machinery of the innate immune response based on the type I and III IFN systems that aims to optimally clear viral infections without igniting inflammation unnecessarily and compromising host fitness.
The key factor determining the relative contribution of IFNls and type I IFNs in antiviral defense is viral load. This provides the alarm signal to the immune system which assesses the level of ''danger'' and induces the appropriate type and magnitude of antiviral immunity that is needed for protection. Accordingly, IFNl production is induced both at low and high doses of IAV, while type I IFNs require higher viral loads that are usually reached if initial viral infection cannot be controlled. Although it is not clear how IFNl expression is favored over type I IFNs at low viral loads, this is likely to involve different sensing mechanisms, differential transcription factor utilization, and distinct cellular sources of production. IFNl suffices to limit early viral spread during sublethal IAV infection, without significant contribution from the type I IFN system, while both IFNl and type I IFNs are needed during lethal IAV infection. Thus, there is division of Data are expressed as mean ± SEM of n = 8-10 for the NP staining and n = 10-20 mice for the rest, pooled from two to three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate significant differences compared to WT mice. p.i., post-infection. Please also see Figure S4 . labor between the two IFN systems: IFNls are essential for early viral control within the first days of infection, while type I IFNs become the dominant mediators of antiviral defense thereafter. Central to IFNl-mediated antiviral protection are their effects in the respiratory epithelium. This is the site where IAV primarily replicates and spreads, and it constitutes the main target for the organism's antiviral defense. The observation therefore that IFNls are initially produced by respiratory epithelial cells, and act on them to induce viral resistance and limit early viral infection, is consistent with their role as a front-line antiviral defense. The finding, however, that IFNls also signal on neutrophils to confer optimal protection is more intriguing. Neutrophils are potent phagocytic cells that act at the epithelial barrier to clear infected dying epithelial cells, inactivate infectious virions, and limit viral spread to neighboring cells . They need, therefore, to possess mechanisms that protect them from becoming targets of the infection, deal with the uptaken viral load, and preserve their overall functionality. Our data now suggest that this is initially provided by IFNls produced by respiratory epithelial cells. IFNls induce the expression of numerous ISGs in neutrophils that interfere with viral entry (IFITM family), degrade viral RNA (OAS and IFIT proteins), inhibit virus translation and replication (ISG15, ISG20, OAS, GBP, and IFI proteins), and suppress virus packaging and exit from cells (ISG15, BST2, RASD2) (Iwasaki and Pillai, 2014) . These exhibit combinatorial antiviral activities and therefore act together to induce the net effect observed. Type I IFNs are also important in this process but come later on as a second level of control. Our findings therefore highlight the importance of the type I and type III IFN systems in the coordinated induction of viral resistance in neutrophils and explain why neutrophils express uniquely high amounts of IFNlR among all leukocytes.
Although IFNls and type I IFNs share antiviral activities during infection, they also exhibit an unexpected fundamental functional difference: their opposing role in inflammation. Absence of a functional type III IFN system in Ifnlr1 À/À mice led to a higher inflammatory burden early on. This is due either to higher viral loads in Ifnlr1 À/À mice, causing more inflammation, or to yetunidentified anti-inflammatory processes triggered by IFNls. In support of the former scenario, Ifnlr1 À/À mice exhibited markedly upregulated IFNa amounts, while targeted cell-specific IFNlR1 deletion at the respiratory epithelium resulted in higher viral burden accompanied by higher inflammation. Still, the possibility that IFNls also exert direct anti-inflammatory or immunoregulatory effects cannot be excluded. On the contrary, absence of a functional type I IFN system reduced the first wave of pro-inflammatory cytokine and chemokine production. This, however, was transient, as compensatory mechanisms were subsequently induced, leading to an aberrant pro-inflammatory response, worsening immunopathology. At the core of the inflammatory response during early IAV infection lie neutrophils. These cells are primarily responsible for the first wave of pro-inflammatory cytokine and chemokine production, including TNF and IL-1b, and account for early immunopathology and acute lethality at higher viral doses (Brandes et al., 2013) . Although neutrophils respond to both IFNs to upregulate antiviral genes and PRRs, they express proinflammatory mediators only in response to type I IFNs. This explains the higher inflammatory burden observed in Ifnlr1 À/À mice, which exhibit markedly increased IFNa expression, and the lower production of pro-inflammatory mediators in Ifnar1
mice. This is not related to reduced infiltration of neutrophils, as their numbers are not significantly altered in Ifnar1 À/À animals.
On the contrary, neutrophils are increased in Ifnlr1 À/À mice, but it is not clear that this is due to a direct inhibitory effect of IFNls in neutrophil chemotaxis, as was recently proposed (Blazek et al., 2015) . The importance of both IFN systems in antiviral defense and protection against IAV infection is further highlighted by their role in long-term survival. Ifnlr1
À/À mice exhibit increased lethality which is due to their compromised ability to achieve early viral control, leading to overactivation of the type I IFN system in an effort to contain infection; however, this also heightens neutrophil activation and inflammation, causing more collateral destruction. On the contrary, increased lethality in Ifnar1
and Ifnlr1 À/À Ifnar1 À/À mice can be attributed to the initial impairment of antiviral and innate immune responses, leading to higher viral burden and secondary induction of exuberant type I IFNindependent pro-inflammatory responses. At all cases, the net effect is aggravation of pulmonary inflammation and alveolar damage leading to lung dysfunction, the primary cause of death in lethal pneumonia. Although a plethora of studies have described protective roles of type I IFNs in viral infection in the lung (McNab et al., 2015) , the idea that type I IFNs may also exacerbate inflammation and cause damage has only recently been put forward (Davidson et al., 2014) . It has also been suggested that type III IFNs may not share this function, as administration of recombinant IFNl2 does not exhibit pro-inflammatory effects (Davidson et al., 2016) . Moreover, although inflammation has long been considered as a causative factor of IAV-induced morbidity and mortality, the importance of the early innate proinflammatory circuit involving activated neutrophils and innate cytokines and chemokines such as TNF and IL-1b has only recently been documented (Brandes et al., 2013) . Our study therefore builds on this earlier work by linking type I IFNs with neutrophil activation, cytokine and chemokine production, and early inflammation, and by adding IFNls as key regulators of this process that prevent overt immune activation and tissue damage. This helps explain the yin and yang of early innate inflammation, with important therapeutic implications. This study expands our current understanding of the biology of IFNls. Several studies have established unique antiviral activities of IFNls in the gastrointestinal tract that cannot be compensated by type I IFNs (Herná ndez et al., 2015; Mahlakõ iv et al., 2015; Nice et al., 2015; Pott et al., 2011) . They have also revealed additional functions of IFNls in adaptive immunity, Th2 cell differentiation, and regulatory T cell development (Dai et al., 2009; Koltsida et al., 2011; Mennechet and Uzé , 2006) , as well as the tightening of the blood-brain barrier (Lazear et al., 2015a) . However, in the respiratory tract, the ''rate-limiting'' Data are expressed as mean ± SEM of n = 8-16 mice per group for (B), (C), (F), and (I) and n = 19-20 for (D) and (H) pooled from two to three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate significant differences compared to WT mice. p.i., post-infection. Please also see Figure S7 .
role of IFNls has remained controversial. Despite notable differences between Ifnlr1
survival and viral load, it has proven difficult to identify variances between Ifnlr1 À/À and WT mice and to assign unique non-redundant roles to IFNls in antiviral immunity (Ank et al., 2008; Mordstein et al., 2008 Mordstein et al., , 2010 . Our study therefore solves this puzzle by demonstrating that early viral spread and sublethal infections are mostly controlled by IFNls, while their importance can be masked by type I IFNs at later time points and in the presence of higher viral loads. Moreover, our study widens the spectrum of activities of IFNls by uncovering their key role in balancing the neutrophil anti-microbial and pro-inflammatory state, limiting immunopathology overall. The ability of IFNls to mediate antiviral defense without activating inflammation offers exciting new opportunities for therapeutic intervention. The observation that PEG-IFNl administration in established IAV infection not only rapidly reduces viral load but also tempers down the type I IFN-dependent pro-inflammatory response, reduces weight loss, and improves lung function, and survival demonstrates the potency of the treatment. As IFNls possess desirable pharmacological properties and a safer drug profile than type I IFNs (Muir et al., 2010) , they constitute promising new candidates for the treatment of a wide range of conditions ranging from IAV-induced pneumonia and other common respiratory infections to asthma exacerbations and ARDS.
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EXPERIMENTAL MODEL AND SUBJECT DETAIL Mice
Wild-type (WT), Ifnar1 À/À and S100a8-Cre-ires/GFP (S100a8 Cre ) mice on a C57BL/6J genetic background were purchased from Jackson Laboratories and further bred in our animal facility. Sftpc-cre (Sftpc fl/fl mice were crossed with Sftpc Cre or S100a8 Cre mice, the following primers were used:
Fw: 5 0 -TTCGGCTATACGTAACAGGG-3 0 and Rev: 5 0 -TCGATGCAACGAGTGATGAG-3 0 . A 500bp fragment is amplified when Cre recombination has taken place. All mice were housed in specific-pathogen free (SPF) conditions in full compliance with FELASA recommendations. All procedures had received approval from Institutional and Regional Ethical Review Boards.
Ifnl2-reporter (Ifnl2 Egfp ) mice were generated through subcontracting to Artemis-Taconic Inc. In brief, the T2A-Egfp coding sequence was inserted in between of the last codon and the STOP codon of the Ifnl2 exon 5, respecting the Ifnl2 translation frame. The human Growing Hormone polyadenylation signal (hGHpA) was inserted dowstream of the STOP codon from the Egfp in order to stop transcription. The positive selection marker (Puromycin Resistance -PuroR) was flanked by FRT sites and inserted downstream of the hGHpA. The targeting vector was generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and transfected into the Taconic Artemis C57BL/6N Tac ES cell line. Homologous recombinant clones were isolated using positive (PuroR) and negative (Thymidine kinase-Tk) selections. The constitutive KI allele was obtained after Flp-mediated removal of the selection marker. The resulting allele expresses a chimeric transcript harboring the Ifnl2 exons 1 to 5 fused with the T2A and the Egfp sequences. The presence of the T2A sequence induces a co-translational cleavage between the IFNl2-T2A and the EGFP proteins, resulting in coexpression of the IFNl2-T2A and the EGFP proteins under the control of the endogenous Ifnl2 promoter. Genetic screening of Ifnl2-T2A-Egfp mice, hence termed Ifnl2
Egfp reporter mice, was carried out by conventional PCR on genomic tail DNA using the following primers: Fw: 5 0 -ACGTCCAGACACAGCATAGG-3 0 and Rev: 5 0 -GCTATAAATTAAGGTGTGGTCTTGG-3 0 , while the following control primers were used to detect the integrity of the genomic DNA: Fw: 5 0 -GAGACTCTGGCTACTCATCC-3 0 and Rev: 5 0 -CCTTCAGCAAGAGCTGGGGAC-3 0 .
Viruses Purified A/PR/8/34 (H1N1) influenza virus (IAV) was purchased from Charles River Laboratories. Infectious viral load was determined by cytopathic effect (CPE) of the titrated viral stock in 96-well culture plates containing low-passage MDCK cells (kindly provided by Dr. Ross Walton, Imperial College London). Titers were expressed as TCID50 per ml virus stock and converted into plaque-forming units (pfu) with the Equation 0.7 PFU = 1 TCID50. To estimate the 50% lethal dose (LD50) of IAV, groups of 6-to 8-wk-old mice were infected with serial dilutions of the viruses in 40 mL of sterile PBS. Littermates of the same sex were randomly assigned to experimental groups. Mice were monitored for 30 days p.i. for body weight loss and morbidity.
METHOD DETAILS
Infection of mice and treatments 6-8 week-old male mice were anesthetized with intraperitoneal injection of 0.051 ml/10 g bodyweight of a mixture of ketamine (20 mg/ml, Merial SAS, France), xylazine (1.3 mg/ml, Bayer AG) and atropine (1.5 mg/ml, Demo SA), and were intranasally infected with various doses of IAV. For experiments with Sftpc Cre Ifnlr1 fl/fl and S100a8 Cre Ifnlr1 fl/fl mice, female animals were also used. Infectious doses were supplied in a volume of 40 mL in sterile PBS. Littermates of the same sex were randomly assigned to experimental groups. Bronchoalveolar lavage fluid (BAL) and lungs were collected upon sacrifice at various time-points post-infection. For the therapeutic protocol, 5 or 10 mg of recombinant mouse pegylated IFNl2 (PEG-IFNl) (Bristol-Myers Squibb Inc) were administered i.n., in a volume of 40 ml, at day 2 or day 1 post-infection in anesthetized mice as indicated. For survival experiments, 10 mg PEGIFNl were administered i.n. once or three times under isofluorane-based anesthesia. All animal experiments were performed in accordance with local institutional and national guidelines and regulations.
Viral load assessment
Viral load was determined in the influenza-infected animals by detection of the IAV Ns1 RNA in the right lungs by qPCR primers published elsewhere (Brandes et al., 2013) and by detection of the IAV HA protein in the BAL by sandwich ELISA kit (Sino Biological). Infectious virus titers in BAL, and sorted neutrophils (CD45 + CD11b + Ly6G + ) from BAL of IAV-infected mice were determined in MDCK cells by plaque assay. Briefly, aliquots of 200 mL of BAL, undiluted or 10-fold serially diluted, were inoculated into confluent monolayers of MDCK cells in 12-well culture plates. Alternatively, sorted neutrophils were centrifuged at 2000 rpm for 10 min, pellets resuspended in serum-free DMEM medium and their concentration adjusted to 10 6 cells/ml. After freezing and thawing cells twice to release the virus, lysates were centrifuged at 13000 rpm to remove debris and 200 ml, undiluted or 10-fold serially diluted, were used for the inoculation. Following 1 hr incubation at 37 C, 5% CO 2 , BAL and lysates were removed and each well was overlaid with MEM supplemented with 2 mg per ml TPCK treated trypsin (Sigma) and 2% agarose. After 3 days incubation, plaques were visualized with crystal violet and counted. The virus titers in BAL are presented as pfu/ml and in sorted cells as pfu/2x10 5 cells.
Measurements of lung mechanisms
Measurements of lung mechanics were performed in anesthetized mechanically ventilated mice using FlexiVent (SciReq). Briefly, mice anesthetized with intra-peritoneal injection of 0.051 ml/10 g bodyweight of a mixture of ketamine (20 mg/ml, Merial SAS) and xylazine (1.3 mg/ml, Bayer AG). The trachea was exposed, cannulated with a blunted metal 18-gauge needle and connected to the computer-controlled small animal ventilator FlexiVent (SciReq). Animals were ventilated with a tidal volume of 8 ml/kg, at a normal respiratory rate (150 breaths/minute). A positive end-expiratory pressure (PEEP) of 0.2 kPa was established by placing the expiratory line in a water trap. Each animal was paralyzed with intra-peritoneal injection of 0.05 ml/10 g bodyweight of rocuronium bromide (0.01mg/ml, N.V. Organon) to suppress spontaneous breathing and allowed to equilibrate on the ventilator. The lung volume history of the mice was standardized prior to measurement of lung mechanics using three deep inflations at total lung capacity. The dynamic compliance, which reflects the stiffness of the lung, and the total lung resistance which assesses the extent of constriction in the lungs were analyzed. Individual values represent the average of three replicate measurements.
BAL analysis and differential cell counts Bronchoalveolar lavage (BAL) of the whole lung was performed with 0.5 mL saline for two times via a tracheal cannula. BAL was collected and an aliquot was stained with trypan blue solution for viability and cell number determination using Neubauer chamber. Samples were centrifuged at 2000 rpm for 10 min in a microcentrifuge. Cells were pelleted onto glass slides via cytospin centrifugation at 600 rpm for 3 min, stained with May-Grumwald-Giemsa and differential cell counts for neutrophils, macrophages, lymphocytes and eosinophils was performed. Supernatants were analyzed for TNF, IL-1b, IL-6, IFNg, G-CSF, CCL2, CCL3, CCL4, CXCL1, CXCL5, CXCL9 and CXCL10 presence using Milliplex technology on a Luminex 200 System according to the manufacturer's instructions (Merck Millipore). Sandwich ELISA kits were used for the detection of mouse IFNa (eBioscience), IFNb (Biolegend) and IFNl (R&D Systems).
RNA isolation from lungs and qPCR
Collected right lung lobes were immediately snap-frozen in liquid nitrogen and placed in À80 C for prolonged storage. Frozen lungs were homogenized in TriReagent (Sigma-Aldrich) and RNA isolation was performed through phase separation, according to standard protocols. RNA concentration and integrity was determined spectrophotometrically and electrophoretically, respectively. 2 mg of the isolated RNA were treated with RQ1 DNase (Promega) and used for cDNA synthesis with the M-MLV reverse transcriptase (Promega) according to the manufacturer's instruction. For transcriptional analysis of mouse lungs, real-time quantitative PCR was performed with iTaq Universal SYBR Ò Green Supermix (Biorad). Relative amounts of mRNA expression were normalized to Gapdh or Ppia and calculated according to the DDCT method. The primer pairs used are described in Table S4 . cDCs. Purified DC subsets were cultured for 12h in complete RPMI medium [RPMI-1640 + 10% FBS + 1% P/S (Final: 50 U/ml Penicillin and 50 mg/ml Streptomycin) + 1% non-essential amino acids + 2.5 mmol/L HEPES Buffer + 50 mM b-mercaptoethanol] in the presence of 100 mg/ml poly(I:C) (Invivogen) for CD24 + cDCs or 5 mM A-Class CpG ODN1585 (Invivogen) for CD11b + cDCs and pDCs. At the end of the incubation, cells were analyzed on a FACS Aria IIu (BD Biosciences) and sorted for EGFP + and EGFP -cells.
Sorted cells were used for RNA isolation with the RNeasy Micro kit (QIAGEN) according to the manufacturer's instructions. cDNA synthesis was performed with the PrimeScript TM RT reagent Kit (Takara) and the cDNA was used for the detection of Egfp and Ifnl (both Ifnl2 and Ifnl3) genes by quantitative real-time PCR using the iTaq Universal SYBR Green Supermix (Biorad). Relative amounts of mRNA expression were normalized to Gapdh and calculated according to the DDCT method. The primer pairs used are described in Table S4 .
Immunohistology and immunofluorescence
For immunohistology, immediately after euthanasia, lungs were inflated through tracheotomy to 17 cm hydrostatic pressure with 10% buffered formalin and kept overnight at RT. They were then transferred in 50% ethanol prior to paraffin embedding. 5 mm thick sections from the left lung lobe were cut in the sagital plane at the level of the respiratory tree for staining with hematoxylin and eosin (H&E).
For immunofluorescence, left lungs were inflated with 4% paraformaldehyde and kept at 4 C overnight. The next day tissues were transferred in 30% sucrose in PBS prior to OCT embedding (Tissue-Tek; Sakura). 10 mm thick cryosections were cut from the left lung lobe in the sagital plane at the level of the respiratory tree, fixed for 10 min in 4% PFA and permeabilized for 15 min with 0.2% Triton X-100/PBS, after 30 min antigen retrieval with sodium citrate at 80 C. Tissues were blocked with 5% donkey serum and stained overnight at 4 C with an anti-EPCAM mAb (2.5 mg/ml, eBioscience) or an anti-Ly6G mAb (5 mg/ml, Bio-X-Cell) or anti-CD45 mAb (2.5 mg/ml, BD PharMingen) in combination with anti-proSP-C mAb (1:500, Merck Millipore). After washes with PBS, sections were treated with the appropriate secondary antibodies [anti-rat Alexa 647 (ThermoFisher Scientific) or anti-rat Alexa 488 or antirabbit Alexa 647 (Jackson ImmunoResearch)] for 1 hr at room temperature, in the dark. Further washing was followed by overnight staining at 4 C with a chicken anti-GFP polyclonal antibody (1:10,000, Abcam). Sections were washed with PBS and then processed for endogenous biotin blocking (Avidin/Biotin Blocking Kit, Vector laboratories) followed by incubation with an anti-chicken biotin conjugated antibody (Santa Cruz Biotechnology) for 1 hr at room temperature. GFP signal amplification was achieved by incubation with HRP-streptavidin and an Alexa Fluor 568 tyramide reagent as described by the manufacturer (TSA TM Kit #24, ThermoFisher Scientific). For NP staining, sections were incubated with a FITC-conjugated IAV anti-NP antibody (1:20, ThermoFisher Scientific) for 1 hr at room temperature in the dark. Nuclei were stained with 2.5 mg/ml DAPI (Calbiochem) in PBS. Sections were mounted with Prolong Diamond mounting medium (ThermoFisher Scientific), coverslipped and visualized with a Leica TCS-SP5II Confocal Microscope.
Flow cytometry and cell sorting
For flow cytometric cell sorting, lungs from PBS and influenza-infected animals were perfused via the right cardiac ventricle with PBS and then immediately harvested. Lungs were minced in small pieces and digested with 3 mL of a solution of collagenase IV (0.5 mg/ml, Roche) in PBS containing 1% FBS. The mixture was incubated for 1h at 37 C, and any remaining pieces were further dispersed by pipetting. Cells were passed through 100 mm cell strainer, resuspended at 1 X 10 7 cells/ml in PBS containing 1% FBS and 2.5 mM EDTA (FACS buffer) and stained for flow cytometry. Unspecific staining was minimized with Fc blocking with anti-mouse CD16/32 antibody through pre-incubation for 15 min with 10% S/N of 2.4G2 cell culture. Dead cells were stained with DAPI dye (Calbiochem) at 0.25 mg/ml. Cells were incubated with primary anti-mouse antibodies for 30 min at 4 C in the dark at a concentration of 1 mg/ml for anti-mouse MHC II (IA/IE), and at 2 mg/ml for the rest of the antibodies. Stained cells were acquired on a FACS Aria IIu (BD Biosciences) and sorted for epithelial cells ( ). Data were analyzed with FACSDIVA software (BD Biosciences). Sorted cells were centrifuged at 3500 rpm for 5 min in a microcentrifuge and pellets were used for RNA isolation with the RNeasy Micro kit (QIAGEN) according to the manufacturer's instructions. cDNA synthesis was performed with the PrimeScript TM RT reagent Kit (Takara). cDNA was then used for the detection of genes by quantitative real-time PCR using the iTaq Universal SYBR Green Supermix (Biorad). Relative amounts of mRNA expression were normalized to Gapdh and calculated according to the DDCT method.
Alternatively, after staining with antibodies, cells were fixed with 4% PFA for 10 min at RT, and permeabilized with a solution of 0.5% saponin in FACS buffer. Intracellular unspecific staining was minimized with Fc blocking with anti-mouse CD16/32 antibody through pre-incubation for 15 min with 10% S/N of 2.4G2 cell culture. Following that, cells were stained intracellularly with FITC-conjugated influenza A anti-NP antibody (10 mg/ml, ThermoFisher Scientific) for 30 min at 4 C in the dark. At the end of the incubation, cells were washed with permeabilization buffer and then with FACS buffer and analyzed on a FACS Aria IIu (BD Biosciences).
Neutrophil isolation and RNA-Seq analysis
For neutrophil isolation, bone marrow cells were flushed from femora and tibiae of WT C57BL/6J male mice. Suspensions were passed through a 40 mm cell strainer and cells were washed in PBS. RBC lysis was performed with the Red Blood Cell lysis buffer (Sigma-Aldrich). Neutrophils were purified to high purity with the EasySep Mouse Neutrophil Enrichment Kit (StemCell Technologies), according to the manufacturer's instructions. Purity was validated by flow cytometry on a FC500 cytometer (Beckman Coulter), where neutrophils were identified as CD11b + Gr-1 + cells. Purified neutrophils were plated at 1x10 6 cells/ml in 24-well plates and left untreated or cultured for 1, 2, 4, 6, 8 or 22 hr in complete RPMI medium in the presence of 100 ng/ml of IFNa2 or IFNl3 (eBioscience). At the end of the incubation, cells were harvested for RNA isolation with the RNeasy Micro kit (QIAGEN) and RNA samples were treated with DNase I (QIAGEN) according to the manufacturer's instructions. cDNA synthesis was performed with the PrimeScript TM RT reagent Kit (Takara). cDNA was then used for the detection of genes by quantitative real-time PCR using the iTaq Universal SYBR Green Supermix (Biorad). Relative amounts of mRNA expression were normalized to Gapdh and calculated according to the DDCT method. Alternatively, neutrophils were plated at 5x10 5 cells/well in 96-well plates and left untreated or cultured for 8h in complete RPMI medium in the presence of 25-200 ng/ml of IFNa2 or IFNl3 (eBioscience). At the end of the incubation, S/N were harvested and used for IL-6 and TNF cytokine determination with sandwich ELISA (Biolegend), according to the manufacturer's instructions. For RNA-seq analysis, purified neutrophils were left untreated or cultured for 2, 4, 8, 16 or 24h either with 100 ng/ml of IFNa2 or IFNl3 (eBioscience). Each condition was performed in biological triplicates. At the end of the incubation, cells were harvested and total RNA was purified with the RNeasy Micro kit (QIAGEN). RNA samples were treated with DNase I (QIAGEN) and quantified on a NanoDrop (Thermo Scientific). RNA seq libraries were prepared with the TruSeq RNA Library Prep Kit v2 (Illumina) according to the manufacturer's instructions. Quality of the libraries was validated with an Agilent DNA 1000 kit run on an Agilent 2100 Bioanalyzer. Bar-coded cDNA libraries were pooled together in equal concentrations in one pool per biological tripicate, and were sequenced on a HiSeq2000 (Illumina) at the Genomics Core Facility of EMBL (Heidelberg, Germany) or the Greek Genome Center (Biomedical Research Foundation, Academy of Athens, Athens, Greece).
Transcriptomics analyses
Samples sequenced on HiSeq 2000 or NextSeq500 (Illumina) were analyzed using standard protocols. Briefly, raw reads were preprocessed using FastQC v.0.11.2 and cutadapt v.1.6, and then mapped to the mouse genome (Mus musculus UCSC version mm10) using the TopHat version 2.0.13, Bowtie v.1.1.1 and Samtools version v.1.1. The read count table was produced using HTSeq v.0.6. Following filtering of raw read counts with a threshold of 50 in at least one dataset, resulting in a total of 11458 genes, DESeq2 analysis was performed. This returned the log2foldchanges of the treatment compared to control for each time point. Differentially expressed gene transcripts were selected based on an adjusted p-value cutoff of 0.01 (FDR 1%). 6072 genes were differentially expressed in at least one of all possible pairwise comparisons across the 15 experimental conditions. Heatmaps and k-means clustering were performed using TM4 MeV v.4.8.
QUANTITATION AND STATISTICAL ANALYSIS
Data were analyzed on GraphPad Prism software. Statistical significance of differences was assessed using the parametric Student's two-tailed t test for normally distributed data and the nonparametric Mann-Whitney U (MWW) test for skewed data that deviate from normality. Kaplan-Meier survival curves were analyzed with the log-rank test. Differences were considered significant when p < 0.05.
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Data Resources
The raw RNA-seq data have been deposited at GEO (http://www.ncbi.nlm.nih.gov/geo/) under BioProject accession number PRJNA311166.
